0001047469-18-004736.txt : 20180625 0001047469-18-004736.hdr.sgml : 20180625 20180625171754 ACCESSION NUMBER: 0001047469-18-004736 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20180625 DATE AS OF CHANGE: 20180625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Senseonics Holdings, Inc. CENTRAL INDEX KEY: 0001616543 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823] IRS NUMBER: 471210911 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-224057 FILM NUMBER: 18917701 BUSINESS ADDRESS: STREET 1: 20451 SENECA MEADOWS PARKWAY CITY: GERMANTOWN STATE: MD ZIP: 20876 BUSINESS PHONE: (301) 515-7260 MAIL ADDRESS: STREET 1: 20451 SENECA MEADOWS PARKWAY CITY: GERMANTOWN STATE: MD ZIP: 20876 FORMER COMPANY: FORMER CONFORMED NAME: ASN Technologies, Inc. DATE OF NAME CHANGE: 20140813 424B5 1 a2236124z424b5.htm 424B5

Use these links to rapidly review the document
TABLE OF CONTENTS

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-224057

The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED JUNE 25, 2018

Preliminary Prospectus Supplement
(To Prospectus Dated April 19, 2018)

$80,000,000

Common Stock

We are offering shares of our common stock. Our common stock is listed on the NYSE American under the symbol "SENS." The last reported sale price of our common stock on the NYSE American on June 22, 2018 was $4.91 per share.

We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements.

Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.

The underwriter has agreed to purchase shares of our common stock from us at a price of $ per share. We have granted the underwriter an option for 30 days from the date of this prospectus supplement to purchase up to additional shares of our common stock. We estimate that the proceeds to us in this offering will be approximately $ million, or approximately $ million if the underwriter exercises in full its option to purchase additional shares, in each case before deducting estimated offering expenses payable by us. The underwriter proposes to offer the shares of our common stock from time to time for sale in one or more transactions on the NYSE American, in the over-the-counter market, through negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, subject to receipt and acceptance by it and subject to its right to reject any order in whole or in part. We have agreed to reimburse the underwriter for certain expenses in connection with this offering. See "Underwriting."

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Delivery of the shares of our common stock is expected to be made on or about June , 2018.

BTIG

Prospectus Supplement dated , 2018.

Table of Contents

TABLE OF CONTENTS

PROSPECTUS SUPPLEMENT


ABOUT THIS PROSPECTUS SUPPLEMENT			S-ii
PROSPECTUS SUPPLEMENT SUMMARY			S-1
RISK FACTORS			S-6
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS			S-8
USE OF PROCEEDS			S-10
DILUTION			S-11
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS			S-12
UNDERWRITING			S-16
LEGAL MATTERS			S-20
EXPERTS			S-20
WHERE YOU CAN FIND MORE INFORMATION			S-20
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE			S-20

PROSPECTUS


ABOUT THIS PROSPECTUS			1
SUMMARY			2
RISK FACTORS			8
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS			8
RATIO OF EARNINGS TO FIXED CHARGES			9
USE OF PROCEEDS			9
DESCRIPTION OF CAPITAL STOCK			10
DESCRIPTION OF DEBT SECURITIES			15
DESCRIPTION OF WARRANTS			24
LEGAL OWNERSHIP OF SECURITIES			27
PLAN OF DISTRIBUTION			31
LEGAL MATTERS			33
EXPERTS			33
WHERE YOU CAN FIND MORE INFORMATION			33
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE			34

S-i

Table of Contents

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is part of a "shelf" registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, and is in two parts. The first part is this prospectus supplement, which describes the specific terms of this common stock offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference in the accompanying prospectus—the statement in the document having the later date modifies or supersedes the earlier statement.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

We have not authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement or in the accompanying prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein or therein is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled "Where You Can Find More Information" and "Incorporation of Certain Information by Reference" in this prospectus supplement and in the accompanying prospectus.

We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

Unless the context indicates otherwise, as used in this prospectus supplement and the accompanying prospectus, the terms "Senseonics," "the Company," "we," "us" and "our" refer to Senseonics Holdings, Inc. and, where appropriate, our subsidiaries. We use Senseonics, the Senseonics logo and Eversense, Eversense XL as trademarks in the United States and other countries. All other trademarks or trade names referred to in this prospectus supplement and the accompanying prospectus are the property of their respective owners.

S-ii

Table of Contents

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights selected information contained elsewhere in this prospectus supplement and the accompanying prospectus and in the documents we incorporate by reference. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus supplement and the accompanying prospectus carefully, especially the risks of investing in our common stock discussed under "Risk Factors" beginning on page S-6 of this prospectus supplement and under similar headings in our Annual Report on Form 10-K for the year ended December 31, 2017 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which are incorporated by reference in this prospectus supplement, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision.

Company Overview

We are a medical technology company focused on the design, development and commercialization of glucose monitoring products to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our continuous glucose monitoring, or CGM, systems, Eversense and Eversense XL, are reliable, long-term, implantable CGM systems that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days, respectively, as compared to six to fourteen days for currently available CGM systems. We believe Eversense and Eversense XL will provide people with diabetes with a more convenient method to monitor their glucose levels in comparison to the traditional method of self-monitoring of blood glucose, or SMBG, as well as currently available CGM systems. In our U.S. pivotal clinical trial, we observed that Eversense measured glucose levels over 90 days with a degree of accuracy superior to that of other currently available CGM systems. On June 21, 2018, our Eversense System received approval from the U.S. Food & Drug Administration for marketing in the United States and we intend to promptly begin distributing Eversense in the United States. Eversense and Eversense XL are approved for sale in Europe/Middle East and Africa (EMEA).

Diabetes is a chronic, life-threatening disease for which there is no known cure. The disease is caused by the body's inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. If diabetes is not managed properly, it can lead to serious health conditions and complications, including heart disease, limb amputations, loss of kidney function, blindness, seizures, coma and even death. According to the 2017 International Diabetes Federation Atlas, an estimated 425 million people worldwide had diabetes as of the date of the report. The number of people with diabetes worldwide is estimated to grow to 629 million by 2045, driven primarily by growth in Type 2 diabetes and due to various reasons, including changes in dietary trends, an aging population and increased prevalence of the disease in younger people. Diabetes is typically classified into two primary types. Type 1 diabetes is an autoimmune disorder that usually develops during childhood and is characterized by the inability of the body to produce insulin, resulting from destruction of the insulin producing beta cells of the pancreas. Type 2 diabetes is a metabolic disorder that results when the body is unable to produce sufficient amounts of insulin or becomes insulin resistant. People with Type 1 diabetes must administer insulin, either by injection or insulin pump, to survive. People with Type 2 diabetes may require diet and nutrition management, exercise, oral medications or the administration of insulin to regulate blood glucose levels. In the next few years, we expect the growth in sales of CGM systems to be driven primarily by increased penetration of CGM in the Type 1 diabetic population.

S-1

Table of Contents

method of monitoring glucose levels is inconvenient and can be painful and, because each measurement represents a single blood glucose value at a single point in time, it provides limited information regarding trends in blood glucose levels. In contrast, CGM systems are generally less painful and involve the insertion of sensors into the body to measure glucose levels in the interstitial fluid throughout the day and night, providing real-time data that shows trends in glucose measurements. Since CGM measurements from interstitial tissue are inherently less accurate than test-strip measurements made directly from the blood, the FDA and other device regulators historically have required that CGMs be labeled and marketed as "adjunctive" to test-strip measurements, with instructions that patients confirm CGM measurements with test-strip measurements using blood obtained from fingersticks prior to self-medicating. Recent improvements in the accuracy of CGM systems have led to the FDA issuing the first "non-adjunctive" label in 2016. The FDA approval for Eversense has an "adjunctive" label. We plan to file a PMA supplement in the near future for a "non-adjunctive" label. Currently available CGM systems are often inconvenient, requiring frequent sensor replacement and an extra device, called a receiver, to monitor glucose readings, and have limited safety features.

We believe we have an $18.0 billion market potential in the United States for our products and systems. According to the National Diabetes Statistics Report, as of the end of 2015, there are approximately 23 million patients diagnosed with diabetes in the United States. We estimate that 6.9 million of these diabetes patients take insulin.

European Development and Commercialization of Eversense

In May 2016, we received our CE mark for Eversense, which allows us to market and sell Eversense in Europe. In connection with our CE Mark, we have agreed to conduct post-market surveillance activities. In June 2016, we commenced commercialization of Eversense in Sweden through our exclusive distribution agreement with Rubin Medical, or Rubin, which also has the right to distribute Eversense in Norway and Denmark. Rubin markets and sells medical products for diabetes treatment in the Scandinavian region.

In May 2016, we entered into a distribution agreement with Roche Diagnostics International AG and Roche Diabetes Care GmbH, together referred to as Roche, pursuant to which we granted Roche the exclusive right to market, sell and distribute Eversense in Germany, Italy and the Netherlands. In November 2016, we entered into an amendment to the distribution agreement granting Roche the exclusive right to market, sell and distribute Eversense in Europe, the Middle East and Africa, excluding Sweden, Norway, Denmark, Finland and Israel. Roche is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. We began distributing Eversense through Roche in Germany in September 2016 and in Italy and the Netherlands in the fourth quarter of 2016. To date, we have begun distributing Eversense in an aggregate of 13 European countries through Rubin and Roche.

In September 2017, we received the CE Mark for Eversense XL, which is indicated for a sensor life of up to 180 days. Eversense XL began commercialization in Europe in the fourth quarter of 2017. In addition, in February 2018, we received approval to market Eversense NOW, which is an application designed to remotely monitor the Eversense users' CGM data in real time.

United States Development and Commercialization of Eversense

S-2

Table of Contents

40-400 mg/dL range when compared to YSI blood reference values during the 90-day continuous wear period. We also observed a MARD of 9.5% utilizing one calibration point for Eversense across the 40-400 mg/dL range when compared to YSI blood reference values during the 90-day continuous wear period. Based on the data from this trial, in October 2016 we submitted a pre-market approval, or PMA, application to the FDA to market Eversense in the United States for 90-day use. On March 29, 2018, we had a meeting with the FDA Clinical Chemistry and Clinical Toxicology Devices Panel, during which the panel voted that the Eversense benefits outweighed the risks by a count of 8 to 0. The panel also voted 8 to 0 in favor of the safety and 8 to 0 in favor of the efficacy of Eversense.

On June 21, 2018 we received PMA approval from the FDA for the Eversense System. We plan to distribute the Eversense System directly in the United States through our own direct sales and marketing organization. We have received Category III CPT codes for the insertion and removal of the Eversense sensor. We intend to pursue a Category I CPT code in the future.

Recent Developments

On June 21, 2018, we received PMA approval from the FDA for the Eversense System. We plan to distribute the Eversense System directly in the United States through our own direct sales and marketing organization.

On June 22, 2018, third party researchers presented data from a clinical study evaluating the performance of Eversense XL for up to 180 days in pediatrics and adults with diabetes at the American Diabetes Association's 78th Scientific Sessions. In this prospective, unblinded, single-arm, single-center study conducted by LMC Diabetes & Endocrinology in Canada, pediatrics (n=30) and adults (n=6) with diabetes were evaluated on the accuracy and safety of the Eversense XL CGM System through the 180-day study duration. When referenced against a lab analyzer, the findings demonstrated the accuracy of Eversense XL (MARD of 9.4%, 15/15% metric of 83%, and 99.6% of consensus error grid data in zones A and B). Study participants also generally expressed an overall favorable rating of the system. No serious adverse events related to the insertion/removal of the sensor or device were reported. We believe the observations from this study could potentially help inform the design of our future pediatric clinical trials.

Company Information

We were originally incorporated as ASN Technologies, Inc. in Nevada on June 26, 2014. On December 7, 2015, pursuant to a merger agreement and the transactions contemplated thereby, or the Acquisition, we acquired Senseonics, Incorporated, a medical technology company focused on the design, development and commercialization of glucose monitoring systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. From its inception in 1996 until 2010, Senseonics, Incorporated devoted substantially all of its resources to researching various sensor technologies and platforms. Beginning in 2010, the company narrowed its focus to designing, developing and refining a commercially viable glucose monitoring system.

In connection with the Acquisition, we reincorporated in Delaware and changed our name to Senseonics Holdings, Inc. Upon the closing of the Acquisition, Senseonics, Incorporated merged with a wholly-owned subsidiary of ours formed solely for that purpose and became our wholly-owned subsidiary.

Our principal executive offices are located at 20451 Seneca Meadows Parkway, Germantown, Maryland 20876-7005. Our telephone number is (301) 515-7260. Our website is located at http://www.senseonics.com. We do not incorporate by reference into this prospectus supplement the information on, or accessible through, our website, and you should not consider it as part of this prospectus supplement.

S-3

Table of Contents

The Offering


Common Stock offered by us		shares
Common Stock to be outstanding immediately after this offering		shares (or shares if the underwriters exercise in full their option to purchase additional shares)
Option to purchase additional shares		We have granted the underwriter an option for 30 days from the date of this prospectus supplement to purchase up to additional shares of our common stock.
Use of proceeds		We estimate that the net proceeds to us in this offering will be approximately $ million, or approximately $ million if the underwriter exercises in full its option to purchase additional shares, in each case after deducting estimated offering expenses payable by us. We plan to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities to begin commercialization of Eversense in the United States, to fund continued research and development of future configurations of Eversense, and for working capital and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus supplement. See "Use of Proceeds."
Risk factors		You should read the "Risk Factors" section of this prospectus supplement and in the documents incorporated by reference herein for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
NYSE American symbol		"SENS"

The number of shares of our common stock to be outstanding after this offering is based on 137,240,202 shares of our common stock outstanding as of March 31, 2018 and excludes:

•: 20,323,788 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2018, at a weighted-average exercise price of $1.82 per share;
•: 14,070 shares of our common stock issuable upon the vesting of outstanding restricted stock units as of March 31, 2018;
•: 4,221,312 shares of our common stock issuable upon the exercise of warrants outstanding as of March 31, 2018, at a weighted-average exercise price of $1.86 per share;
•: 6,347,019 shares of our common stock reserved for future issuance under our equity incentive plans consisting of (a) 3,242,496 shares of common stock reserved for future issuance under our amended and restated 2015 Equity Incentive Plan, or the 2015 Plan, and (b) 3,104,523 shares of common stock reserved for issuance under our 2016 Employee Stock Purchase Plan, or the 2016 ESPP; and

S-4

Table of Contents

•: 22,503,750 shares of our common stock issuable upon the conversion of our convertible senior subordinated notes, or the 2023 Notes, outstanding as of March 31, 2018.

Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options and warrants and no vesting of restricted stock units described above and no exercise by the underwriters of their option to purchase additional shares of our common stock.

S-5

Table of Contents

RISK FACTORS

Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and uncertainties described below together with all other information contained in this prospectus supplement, the accompanying prospectus and in our filings with the SEC that we have incorporated by reference into this prospectus supplement and the accompanying prospectus. If any of the following risks actually occurs, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment.

Risks Related to this Offering

After this offering, our executive officers and directors and their affiliates, if they choose to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for approval.

Upon the completion of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering will beneficially own, in the aggregate, shares representing approximately 47.8% of our common stock, based on such stockholders' holdings as of February 1, 2018, and an assumed public offering price of $4.91 per share, the last reported sale price of our common stock on the NYSE American on June 22, 2018 and assuming no exercise by the underwriters of their option to purchase additional shares and no exercise of options and warrants outstanding as of March 31, 2018. As a result, following this offering, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may delay, defer or prevent a change in control of our company, entrench our management and board of directors, or impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.

If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment.

The price of our common stock in this offering is substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our historical net tangible book value per share after this offering. To the extent outstanding options or warrants are exercised, you will incur further dilution. Based on the assumed public offering price of $4.91 per share, the last reported sale price of our common stock on the NYSE American on June 22, 2018, you will experience immediate dilution of $4.48 per share, representing the difference between our as adjusted net tangible book value per share after giving effect to this offering and the assumed public offering price.

Investors in this offering may experience future dilution.

In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into, or exchangeable for, our common stock at prices that may not be the same as the price per share in this offering. We cannot assure you that we will be able to sell shares of our common stock or other related securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering. If the price per share at which we sell additional shares of our common stock or related securities in future transactions is less than the price per share in this offering, investors who purchase our common stock in this offering will suffer dilution in their investment.

S-6

Table of Contents

We have broad discretion over the use of our cash, cash equivalents and marketable securities, including the net proceeds we receive in this offering, and may not use them effectively.

Our management has broad discretion to use our cash, cash equivalents and marketable securities, including the net proceeds we receive in this offering, to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have an adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash, cash equivalents and marketable securities in a manner that does not produce income or that loses value.

The price of our common stock may be volatile, and you may not be able to resell your shares at prices that are attractive to you.

The trading volume of our common stock has been limited since our common stock began publicly trading on the OTCQB in December 2015 and has remained limited on the NYSE American since our common stock was listed on the NYSE American in March 2016, and there can be no assurance that an active and liquid trading market for our common stock will develop or be sustained. It may be difficult for stockholders to sell their shares of our common stock at prices that are attractive to them, or at all. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products, product candidates or technologies by using our shares of our common stock as consideration. Stockholders may also be unable to sell their shares of common stock at prices that are attractive to them due to fluctuations in the market price of our common stock. Furthermore, if our stockholders sell a substantial number of shares of our common stock, especially if those sales are made during a short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition.

S-7

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These are based on our management's current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the sections titled "Business," "Risk Factors" and "Management Discussion and Analysis of Financial Condition and Results of Operations" incorporated by reference from our Annual Report on Form 10-K for the year ended December 31, 2017 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as well as any amendments thereto, as applicable, filed with the SEC. All statements other than statements of historical fact could be deemed forward-looking, including but not limited to statements about:

•: our ability to maintain regulatory approval of, Eversense in the United States;
•: our ability to maintain regulatory approval of Eversense and Eversense XL in Europe;
•: the clinical utility of Eversense;
•: our ability to develop future generations of Eversense;
•: our ability to access our credit facilities in the future;
•: the timing and availability of data from our clinical trials;
•: the timing of our planned regulatory filings;
•: our future development priorities;
•: our ability to obtain adequate reimbursement and third-party payor coverage for Eversense;
•: our expectations about the willingness of healthcare providers to recommend Eversense to people with diabetes;
•: our commercialization, marketing and manufacturing capabilities and strategy;
•: our ability to comply with applicable regulatory requirements;
•: our ability to maintain our intellectual property position;
•: our estimates regarding the size of, and future growth in, the market for CGM systems;
•: our estimates regarding the period of time for which our current capital resources will be sufficient to fund our continued operations; and
•: our estimates regarding our future expenses and needs for additional financing.

In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue", "target", "seek", "contemplate", and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each such forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

S-8

Table of Contents

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. You should refer to the section titled "Risk Factors" in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements.

As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this prospectus supplement represent our views as of the date of this prospectus supplement. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus supplement.

You should carefully read this prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference, as described in the section titled "Incorporation of Certain Information by Reference," completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

S-9

Table of Contents

USE OF PROCEEDS

We estimate that the net proceeds to us in this offering will be approximately $ million, or approximately $ million if the underwriter exercises in full its option to purchase additional shares, in each case after deducting estimated offering expenses payable by us.

We currently intend to use the net proceeds from this offering to begin commercialization of Eversense in the United States, to fund continued research and development of future configurations of Eversense, and for working capital and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus supplement.

This expected use of our net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our product candidate development, the status of and results from clinical trials, as well as any collaborations that we may enter into with third parties for our product candidates, and any unforeseen cash needs.

As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds from this offering. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending these uses, we expect to invest the net proceeds in short-term, interest bearing obligations, certificates of deposit or direct or guaranteed obligations of the United States. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are readily available to fund our operations.

Based on the planned use of proceeds described above, we believe that the net proceeds from this offering and our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through the end of 2019. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.

S-10

Table of Contents

DILUTION

If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering. Our historical net tangible book value as of March 31, 2018 was $(13.2) million, or $(0.10) per share of common stock. Historical net tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding on March 31, 2018.

After giving effect to the issuance and sale of 16,293,279 shares of our common stock in this offering, based on an assumed public offering price of $4.91 per share, the last reported sale price of our common stock on the NYSE American on June 22, 2018 and after deducting estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2018 would have been $66.6 million, or $0.43 per share. This represents an immediate increase of $0.53 in the as adjusted net tangible book value per share to existing stockholders and immediate dilution of $4.48 in the as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors. The following table illustrates this per share dilution to the new investors purchasing shares of common stock in this offering without giving effect to any exercise by the underwriter of its option to purchase additional shares:


Assumed public offering price per share				$	4.91
Net tangible book value per share as of March 31, 2018	$	(0.10	)
Increase per share attributable to sale of shares of common stock in this offering		0.53

As adjusted net tangible book value per share after this offering					0.43

Dilution per share to new investors in this offering				$	4.48

If the underwriter exercises in full its option to purchase 2,443,991 additional shares, based on an assumed public offering price of $4.91 per share, the last reported sale price of our common stock on the NYSE American on June 22, 2018, the as adjusted net tangible book value will increase to $0.50 per share, representing an immediate increase to existing stockholders of $0.60 per share and an immediate dilution of $4.41 per share to new investors.

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

The information discussed above is based on 137,240,202 shares of our common stock outstanding as of March 31, 2018 and excludes:

•: 20,323,788 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2018, at a weighted-average exercise price of $1.82 per share;
•: 14,070 shares of our common stock issuable upon the vesting of outstanding restricted stock units as of March 31, 2018;
•: 4,221,312 shares of common stock issuable upon the exercise of warrants outstanding as of March 31, 2018, at a weighted-average exercise price of $1.86 per share;
•: 6,347,019 shares of common stock reserved for future issuance under our equity incentive plans consisting of (a) 3,242,496 shares of common stock reserved for future issuance under the 2015 Plan, and (b) 3,104,523 shares of common stock reserved for issuance under the 2016 ESPP; and
•: 22,503,750 shares of common stock issuable upon the conversion of our convertible senior subordinated notes, or the 2023 Notes, outstanding as of March 31, 2018.

To the extent that outstanding options or warrants are exercised, restricted stock units vest, the 2023 Notes are converted or we issue additional shares in the future, there will be further dilution to investors purchasing in this offering.

S-11

Table of Contents

MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS

The following is a general discussion of the material U.S. federal income tax considerations applicable to non-U.S. holders (as defined herein) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. All prospective non-U.S. holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and non-U.S. tax consequences of the purchase, ownership and disposition of our common stock. In general, a non-U.S. holder means a beneficial owner of our common stock (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is not, for U.S. federal income tax purposes:

•: an individual who is a citizen or resident of the United States;
•: a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia;
•: an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
•: a trust if (1) a U.S. court can exercise primary supervision over the trust's administration and one or more U.S. persons have the authority to control all of the trust's substantial decisions or (2) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.

This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements and rulings of the U.S. Internal Revenue Service, which we refer to as the IRS, and judicial decisions, all as in effect as of the date of this prospectus supplement. These authorities are subject to change and to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus supplement.

This discussion is limited to non-U.S. holders who hold shares of our common stock as a capital asset within the meaning of Section 1221 of the Code (generally, for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances, nor does it address any alternative minimum, Medicare contribution, estate or gift tax consequences, or any aspects of U.S. state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, tax-exempt organizations, banks, financial institutions, insurance companies, brokers, dealers or traders in securities, commodities or currencies, tax-qualified retirement plans, holders who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as compensation, holders who hold our common stock as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment, holders deemed to sell our common stock under the constructive sale provisions of the Code, accrual method taxpayers subject to special accounting rules under Section 451(b) of the Code, and certain former U.S. citizens or long-term residents.

In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes) or persons that hold their common stock through such partnerships. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds shares of our common stock, the U.S. federal income tax treatment of a partner in such partnership will generally

S-12

Table of Contents

depend upon the status of the partner and the activities of the partnership. Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our common stock.

There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a non-U.S. holder of the purchase, ownership or disposition of our common stock.

Distributions on Our Common Stock

Distributions, if any, on our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder's investment, up to such holder's adjusted tax basis in the common stock. Any remaining excess will be treated as capital gain from the sale or exchange of such common stock, subject to the tax treatment described below in "Gain on Sale, Exchange or Other Disposition of Our Common Stock."

Subject to the discussion below regarding effectively connected income, backup withholding and foreign accounts, dividends paid to a non-U.S. holder will generally be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence.

Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so requires, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence.

To claim a reduction or exemption from withholding, a non-U.S. holder of our common stock generally will be required to provide (a) a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements to claim the benefit of an applicable income tax treaty between the United States and such holder's country of residence, or (b) a properly executed IRS Form W-8ECI stating that dividends are not subject to withholding because they are effectively connected with such non-U.S. holder's conduct of a trade or business within the United States. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty.

A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.

S-13

Table of Contents

Gain on Sale, Exchange or Other Disposition of Our Common Stock

Subject to the discussion below regarding backup withholding and foreign accounts, in general, a non-U.S. holder will not be subject to any U.S. federal income tax on any gain realized upon such holder's sale, exchange or other disposition of shares of our common stock unless:

•: the gain is effectively connected with a U.S. trade or business of the non-U.S. holder and, if an applicable income tax treaty so requires, is attributable to a permanent establishment or a fixed base maintained in the United States by such non-U.S. holder, in which case the non-U.S. holder generally will be taxed at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). If the non-U.S. holder is a foreign corporation, the branch profits tax described above in "Distributions on Our Common Stock" also may apply;
•: the non-U.S. holder is a nonresident alien individual who is present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by any U.S. source capital losses of the non-U.S. holder; or
•: our common stock constitutes a U.S. real property interest because we are, or have been, at any time during the five-year period preceding such disposition (or the non-U.S. holder's holding period, if shorter) a "U.S. real property holding corporation." Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. Even if we are or become a U.S. real property holding corporation, so long as our common stock remains regularly traded on an established securities market (as defined by applicable U.S. Treasury Regulations), our common stock will be treated as a U.S. real property interest only with respect to a non-U.S. holder that holds more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. In such case, such non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). No assurance can be provided that our common stock will continue to be regularly traded on an established securities market for purposes of the rules described above.

Backup Withholding and Information Reporting

We must report annually to the IRS and to each non-U.S. holder the gross amount of the dividends paid in respect of our common stock and the tax withheld. Non-U.S. holders will have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. A non-U.S. holder generally will not be subject to U.S. backup withholding with respect to payments of dividends on our common stock if it certifies its non-U.S. status by providing a valid IRS Form W-8BEN or W-8BEN-E (or successor form) or W-8ECI, or otherwise establishes an exemption, provided we do not have actual knowledge or reason to know such non-U.S. holder is a U.S. person, as defined in the Code. Dividends paid to non-U.S. holders subject to the U.S. withholding tax, as described above in "Distributions on Our Common Stock," generally will be exempt from U.S. backup withholding.

Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S.

S-14

Table of Contents

or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a non-U.S. broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.

Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder may be allowed as a credit against the non-U.S. holder's U.S. federal income tax liability, if any, and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.

Foreign Accounts

The Code generally imposes a U.S. federal withholding tax of 30% on dividends and the gross proceeds of a disposition of our common stock paid to a "foreign financial institution" (as specifically defined for this purpose), unless such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise qualifies for an exemption from these rules. A U.S. federal withholding tax of 30% also applies to dividends and the gross proceeds of a disposition of our common stock paid to a non-financial foreign entity (as defined in the Code), unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity, or otherwise qualifies for an exemption from these rules. The withholding provisions described above currently apply to dividends paid on our common stock and will generally apply with respect to gross proceeds of a sale or other disposition of our common stock on or after January 1, 2019. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph.

EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAWS.

S-15

Table of Contents

UNDERWRITING

Subject to the terms and conditions set forth in the underwriting agreement between us and BTIG, LLC, as underwriter, we have agreed to sell to the underwriter, and the underwriter has agreed to purchase from us shares of our common stock.

Commission and Expenses

The underwriter has agreed to purchase the shares of our common stock from us at a price of $ per share, which will result in approximately $ of proceeds to us, before deducting estimated offering expenses payable by us. The underwriter proposes to offer the shares of our common stock from time to time for sale in one or more transactions on Nasdaq, in the over-the-counter market, through negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, subject to receipt and acceptance by it and subject to its right to reject any order in whole or in part. The difference between the price at which the underwriter purchases shares and the price at which the underwriter resells such shares may be deemed underwriting compensation. The underwriter may effect such transactions by selling shares of our common stock to or through dealers, and as such dealers may receive compensation in the form of discounts, concessions or commission from the underwriter and/or purchases of shares of our common stock for whom they may act as agents or to who they may sell as principal. We have also agreed to reimburse the underwriter for certain expenses, including up to an aggregate amount of $50,000, as set forth in the underwriting agreement.

We estimate expenses payable by us in connection with this offering will be approximately $200,000.

Listing

Our common stock is listed on the NYSE American under the trading symbol "SENS."

Option to Purchase Additional Shares

We have granted the underwriter an option for 30 days from the date of this prospectus supplement to purchase up to additional shares of our common stock.

No Sales of Similar Securities

We have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 90 days from the date of this prospectus supplement, offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock.

The restriction in the immediately preceding paragraph does not apply in certain circumstances, including:

•: sale of our common stock in this offering;
•: issuances of our common stock or any equity awards pursuant to our employee compensation plans as such plans are in existence on the date of the underwriting agreement;
•: issuances of our common stock pursuant to the vesting or exercises of options, restricted stock units, warrants or rights outstanding on the date of the underwriting agreement; or
•: issuances of securities pursuant to acquisitions or strategic transactions approved by a majority of our disinterested directors, provided that such issuances are not primarily for the purpose of raising capital.

S-16

Table of Contents

In addition, our officers and directors and their affiliated entities have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 60 days from the date of this prospectus supplement:

•: offer, pledge, sell, assign, transfer, lend, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock, or exercise any right with respect to the registration of any of the foregoing, or file or cause to be filed any registration statement in connection therewith, under the Securities Act;
•: enter into any swap or any other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of our common stock; or
•: engage in any short selling of any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock.

BTIG, LLC may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriter and any of our stockholders who have executed a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period.

Market Making, Stabilization and Other Transactions

The underwriter may make a market in the common stock as permitted by applicable laws and regulations. However, the underwriter is not obligated to do so, and the underwriter may discontinue any market-making activities at any time without notice in its sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable.

The underwriter has advised us that it, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, and certain persons participating in the offering, may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either "covered" short sales or "naked" short sales.

"Covered" short sales are sales made in an amount not greater than the underwriter's option to purchase additional shares of our common stock in this offering. The underwriter may close out any covered short position by either exercising its option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriter will consider, among other things, the price of shares of common stock available for purchase in the open market as compared to the price at which it may purchase shares through the option to purchase additional shares.

"Naked" short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriter must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering.

A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriter for the purpose of fixing or maintaining the price of the common stock. A syndicate covering

S-17

Table of Contents

transaction is the bid for or the purchase of shares of common stock on behalf of the underwriter to reduce a short position incurred by the underwriter in connection with the offering. Similar to other purchase transactions, the underwriter's purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriter to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.

Neither we, nor the underwriter, make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriter is not obligated to engage in these activities and, if commenced, may end any of these activities at any time.

Passive Market Making

The underwriter may also engage in passive market-making transactions in our common stock on the NYSE American in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker's bid, that bid must then be lowered when specified purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriter is not required to engage in passive market making and, if commenced, may end passive market making activities at any time.

Electronic Distribution

A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by the underwriter, selling group members (if any) or their affiliates. The underwriter may agree with us to allocate a specific number of shares of our common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriter on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriter's web site and any information contained in any other web site maintained by any of the underwriter is not part of this prospectus supplement or the accompanying prospectus, has not been approved and/or endorsed by us or the underwriter and should not be relied upon by investors.

Other Activities and Relationships

The underwriter and certain of its respective affiliates are full service financial institutions engaged in a wide range of activities for their own accounts and the accounts of customers, which may include, among other things, corporate finance, mergers and acquisitions, merchant banking, equity and fixed income sales, trading and research, derivatives, foreign exchange, futures, asset management, custody, clearance and securities lending. The underwriter and certain of its affiliates have, from time to time, performed, and may in the future perform, various investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.

In addition, in the ordinary course of their various business activities, the underwriter and certain of its respective affiliates may, directly or indirectly, hold long or short positions, trade and otherwise

S-18

Table of Contents

conduct such activities in or with respect to debt or equity securities and/or bank debt of, and/or derivative products. Such investment and securities activities may involve our securities and instruments. The underwriter and certain of its respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments.

Stamp Taxes

If you purchase shares of our common stock offered in this prospectus supplement, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus supplement.

Notice to Canadian Investors

The shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and that are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable Canadian securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts ("NI 33-105"), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

S-19

Table of Contents

LEGAL MATTERS

The validity of the shares of our common stock offered hereby will be passed upon for us by Cooley LLP, Reston, Virginia. O'Melveny & Myers LLP, San Francisco, California, is counsel for the underwriter in connection with this offering.

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 2 to the consolidated financial statements), which is incorporated by reference in this prospectus supplement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP's report, given on their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.senseonics.com. Our website is not a part of this prospectus supplement and is not incorporated by reference in this prospectus supplement. You may also read and copy any document we file with the SEC at the SEC's Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room.

This prospectus supplement is part of a registration statement that we filed with the SEC. The registration statement contains more information than this prospectus supplement and the accompanying prospectus regarding us and the securities, including certain exhibits and schedules. You can obtain a copy of the registration statement from the SEC at the address listed above or from the SEC's internet site.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to incorporate by reference in this prospectus supplement and the accompanying prospectus much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement and the accompanying prospectus is considered to be part of this prospectus supplement and the accompanying prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus supplement and the accompanying prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus supplement and the accompanying prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement, the accompanying prospectus or any document previously incorporated by reference have been modified or superseded. The SEC file number for the documents incorporated by reference in this prospectus supplement is 001-37717. This prospectus supplement and the accompanying prospectus incorporate by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not

S-20

Table of Contents

deemed to be filed) until the offering of the securities under the registration statement is terminated or completed:

•: our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 13, 2018;
•: our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 10, 2018;
•: our Current Reports on Form 8-K filed with the SEC on January 25, 2018, January 26, 2018 (and related Form 8-K/A), January 30, 2018, March 30, 2018, June 5, 2018 and June 21, 2018 to the extent the information in such reports is filed and not furnished;
•: our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 25, 2018 (other than the portions thereof which are furnished and not filed); and
•: the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on Form 8-A, filed with the SEC on March 11, 2016, including any amendments or reports filed for the purpose of updating such description.

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or phone number:

Senseonics Holdings, Inc.
Attn: R. Don Elsey, Chief Financial Officer
20451 Seneca Meadows Parkway
Germantown, MD 20876-7005
(301) 515-7260

S-21

PROSPECTUS

$200,000,000

Common Stock
Preferred Stock
Debt Securities
Warrants

From time to time, we may offer up to $200,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable anti-dilution provisions.

This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.

This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.

Our common stock is traded on the NYSE American under the symbol "SENS." On March 28, 2018, the last reported sale price of our common stock was $2.79 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the NYSE American or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.

We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled "Plan of Distribution" in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page 8 of this prospectus.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus is April 19, 2018.

TABLE OF CONTENTS


ABOUT THIS PROSPECTUS			1
SUMMARY			2
RISK FACTORS			8
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS			8
RATIO OF EARNINGS TO FIXED CHARGES			9
USE OF PROCEEDS			9
DESCRIPTION OF CAPITAL STOCK			10
DESCRIPTION OF DEBT SECURITIES			15
DESCRIPTION OF WARRANTS			24
LEGAL OWNERSHIP OF SECURITIES			27
PLAN OF DISTRIBUTION			31
LEGAL MATTERS			33
EXPERTS			33
WHERE YOU CAN FIND MORE INFORMATION			33
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE			34

ABOUT THIS PROSPECTUS

This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a "shelf" registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $200,000,000. This prospectus provides you with a general description of the securities we may offer.

Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading "Incorporation of Certain Information by Reference," before investing in any of the securities offered.

THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.

Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.

This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find More Information."

SUMMARY

This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

Unless the context indicates otherwise, as used in this prospectus, the terms "Senseonics," "the Company," "we," "us" and "our" refer to Senseonics Holdings, Inc. and, where appropriate, our subsidiary. We use Senseonics, the Senseonics logo, Eversense and Eversense XL as trademarks in the United States and other countries. All other trademarks or trade names referred to in this prospectus are the property of their respective owners.

Company Overview

We are a medical technology company focused on the design, development and commercialization of glucose monitoring products to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our continuous glucose monitoring, or CGM, systems, Eversense and Eversense XL, are reliable, long-term, implantable CGM systems that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days, respectively, as compared to six to fourteen days for currently available CGM systems. We believe Eversense and Eversense XL will provide people with diabetes with a more convenient method to monitor their glucose levels in comparison to the traditional method of self-monitoring of blood glucose, or SMBG, as well as currently available CGM systems. In our U.S. pivotal clinical trial, we observed that Eversense measured glucose levels over 90 days with a degree of accuracy superior to that of other currently available CGM systems. Our Eversense and Eversense XL systems are currently approved for sale in Europe and we submitted our pre-market approval, or PMA, application for Eversense to the U.S. Food and Drug Administration, or FDA, in October 2016. On March 29, 2018, we had a meeting with the FDA Clinical Chemistry and Clinical Toxicology Devices Panel, during which the panel voted that the Eversense benefits outweighed the risks by a count of 8 to 0. The panel also voted 8 to 0 in favor of the safety and 8 to 0 in favor of the efficacy of Eversense. We anticipate that FDA's decision on our PMA application might occur within two to four months following the panel meeting. If we receive FDA approval, we intend to initiate commercial launch in the United States promptly following the receipt of PMA approval.

survive. People with Type 2 diabetes may require diet and nutrition management, exercise, oral medications or the administration of insulin to regulate blood glucose levels. In the next few years, we expect the growth in sales of CGM systems to be driven primarily by increased penetration of CGM in the Type 1 diabetic population.

In an attempt to maintain blood glucose levels within the normal range, many people with diabetes seek to actively monitor their blood glucose levels. The traditional SMBG method of glucose monitoring requires lancing the fingertips, commonly referred to as fingersticks, multiple times per day and night to obtain a blood drop to be applied to a test strip inside a blood glucose meter. This method of monitoring glucose levels is inconvenient and can be painful and, because each measurement represents a single blood glucose value at a single point in time, it provides limited information regarding trends in blood glucose levels. In contrast, CGM systems are generally less painful and involve the insertion of sensors into the body to measure glucose levels in the interstitial fluid throughout the day and night, providing real-time data that shows trends in glucose measurements. Since CGM measurements from interstitial tissue are inherently less accurate than test-strip measurements made directly from the blood, the FDA and other device regulators historically have required that CGMs be labeled and marketed as "adjunctive" to test-strip measurements, with instructions that patients confirm CGM measurements with test-strip measurements using blood obtained from fingersticks prior to self-medicating. Recent improvements in the accuracy of CGM systems have led to the FDA issuing the first "non-adjunctive" label in 2016. We expect that the approval of the Eversense PMA will have an "adjunctive" label initially. Our plans will be to pursue a "non-adjunctive" label as soon as possible. Currently available CGM systems are often inconvenient, requiring frequent sensor replacement and an extra device, called a receiver, to monitor glucose readings, and have limited safety features.

European Development and Commercialization of Eversense

In September 2017, we received the CE Mark for Eversense XL, which is indicated for a sensor life of up to 180 days. Eversense XL began commercialization in Europe in the fourth quarter of 2017.

In addition, in February 2018, we received approval to market Eversense NOW, which is an application designed to remotely monitor the Eversense users' CGM data in real time.

United States Development of Eversense

In 2016, we completed our Precise II pivotal clinical trial in the United States. This trial, which was fully enrolled with 90 subjects, was conducted at eight sites in the United States. In the trial, we measured the accuracy of Eversense measurements through 90 days after insertion. We also assessed safety through 90 days after insertion or through sensor removal. In the trial, we observed a mean absolute relative difference, or MARD, of 8.5% utilizing two calibration points for Eversense across the 40-400 mg/dL range when compared to YSI blood reference values during the 90-day continuous wear period. We also observed a MARD of 9.5% utilizing one calibration point for Eversense across the 40-400 mg/dL range when compared to YSI blood reference values during the 90-day continuous wear period. Based on the data from this trial, in October 2016 we submitted a pre-market approval, or PMA, application to the FDA to market Eversense in the United States for 90-day use. On March 29, 2018, we had a meeting with the FDA Clinical Chemistry and Clinical Toxicology Devices Panel, during which the panel voted that the Eversense benefits outweighed the risks by a count of 8 to 0. The panel also voted 8 to 0 in favor of the safety and 8 to 0 in favor of the efficacy of Eversense. We anticipate that FDA's decision on our PMA application might occur within two to four months following the panel meeting. However, the ultimate timing of FDA's decision is uncertain and will depend on many factors. Accordingly, we cannot guarantee the timing of receipt of PMA approval, if at all. For commercialization in the United States, we intend to distribute our product through our own direct sales and marketing organization. We have received Category III CPT codes for the insertion and removal of the Eversense sensor. We intend to pursue a Category I CPT code in the future.

Corporate Information

We were originally incorporated as ASN Technologies, Inc. in Nevada on June 26, 2014. On December 7, 2015, pursuant to the Merger Agreement and the transactions contemplated thereby, or the Acquisition, we acquired Senseonics, Incorporated, a medical technology company focused on the design, development and commercialization of glucose monitoring systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. From its inception in 1996 until 2010, Senseonics, Incorporated devoted substantially all of its resources to researching various sensor technologies and platforms. Beginning in 2010, the company narrowed its focus to designing, developing and refining a commercially viable glucose monitoring system.

Our principal executive offices are located at 20451 Seneca Meadows Parkway, Germantown, Maryland 20876-7005. Our telephone number is (301) 515-7260. Our website is located at http://www.senseonics.com. We do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus.

Implications of Being an Emerging Growth Company

We qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from some

of the reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include:

•: being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure;
•: not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;
•: not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;
•: reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
•: not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (b) December 31, 2019; (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous six years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these reduced burdens. For example, we have taken advantage of the reduced reporting requirements with respect to disclosure regarding our executive compensation arrangements, have presented only two years of audited financial statements and only two years of related "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure in our public filings, and have taken advantage of the exemption from auditor attestation on the effectiveness of our internal control over financial reporting. To the extent that we take advantage of these reduced burdens, the information that we provide stockholders may be different than you might obtain from other public companies in which you hold equity interests.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

The Securities We May Offer

We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, up to a total aggregate offering price of $200,000,000 from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

•: designation or classification;
•: aggregate principal amount or aggregate offering price;
•: maturity;

•: original issue discount, if any;

•: rates and times of payment of interest or dividends, if any;
•: redemption, conversion, exchange or sinking fund terms, if any;
•: conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange;
•: ranking;
•: restrictive covenants, if any;
•: voting or other rights, if any; and
•: important U.S. federal income tax considerations.

The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.

This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.

We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement:

•: the names of those underwriters or agents;
•: applicable fees, discounts and commissions to be paid to them;
•: details regarding over-allotment options, if any; and
•: the estimated net proceeds to us.

Common Stock. We may issue shares of our common stock from time to time. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of our common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights.

Preferred Stock. We may issue shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or the rules of any stock exchange or market on which our securities are then traded), to designate up to 5,000,000 shares of preferred stock in one or more series and to determine the designations, voting powers, preferences and rights of each series of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series, any or all of which may be greater than the rights of the

common stock. Any convertible preferred stock we may issue will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the holder's option and would be at prescribed conversion rates.

If we sell any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.

Debt Securities. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or preferred stock. Conversion may be mandatory or at the holder's option and would be at prescribed conversion rates.

The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.

Warrants. We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.

We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered.

RISK FACTORS

Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form 10-K for the year ended December 31, 2017, as updated by any subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors described in the documents referenced above could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and the documents incorporated by reference herein contain forward-looking statements. These are based on our management's current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the sections entitled "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in the documents incorporated by reference herein.

Any statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, these forward-looking statements include statements regarding:

•: the timing of, and our ability to obtain and maintain regulatory approval of, Eversense in the United States;
•: our ability to maintain regulatory approval of Eversense and Eversense XL in Europe;
•: the clinical utility of Eversense;
•: our ability to develop future generations of Eversense;
•: our ability to access our credit facilities in the future;
•: the timing and availability of data from our clinical trials;
•: the timing of our planned regulatory filings;
•: our future development priorities;
•: our ability to obtain adequate reimbursement and third-party payor coverage for Eversense;
•: our expectations about the willingness of healthcare providers to recommend Eversense to people with diabetes;
•: our commercialization, marketing and manufacturing capabilities and strategy;
•: our ability to comply with applicable regulatory requirements;
•: our ability to maintain our intellectual property position;
•: our estimates regarding the size of, and future growth in, the market for CGM systems;

•: our estimates regarding the period of time for which our current capital resources will be sufficient to fund our continued operations; and
•: our estimates regarding our future expenses and needs for additional financing.

In some cases, you can identify forward-looking statements by the words "may," "might," "can," "will," "to be," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "likely," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

You should refer to the "Risk Factors" section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future.

RATIO OF EARNINGS TO FIXED CHARGES

If we offer debt securities and/or preference equity securities under this prospectus, then we will, if required at that time, provide a ratio of earnings to fixed charges and/or ratio of combined fixed charges and preference dividends to earnings, respectively, in the applicable prospectus supplement for such offering.

USE OF PROCEEDS

We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities.

DESCRIPTION OF CAPITAL STOCK

The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.

General

Our amended and restated certificate of incorporation authorizes us to issue up to 250,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share, all of which shares of preferred stock were undesignated as of December 31, 2017. Our board of directors may establish the rights and preferences of the preferred stock from time to time. As of December 31, 2017, we had outstanding 136,882,735 shares of common stock.

Common Stock

Voting Rights

Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our certificate of incorporation and bylaws, our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.

Dividends

Holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.

Liquidation

In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders.

Rights and Preferences

Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.

Registration Rights

We and certain holders of our common stock have entered into a registration rights agreement. The registration rights provisions of this agreement provide those holders with demand, piggyback and Form S-3 registration rights. The shares subject to such rights are referred to herein as "Registrable Shares."

In addition, pursuant to the terms of our certain of our warrants to purchase common stock held by Oxford Finance LLC, or Oxford, Oxford has piggyback registration rights with respect to the shares of common stock issuable upon the exercise of the warrants on the same terms as are set forth in the registration rights agreement.

Demand Registration Rights

The holders of at least a majority of the Registrable Shares in the aggregate, or a lesser percent if the anticipated aggregate offering price would exceed $10.0 million, have the right to demand that we filed up to a total of two registration statements. These registration rights are subject to specified conditions and limitations, including the right of a managing underwriter to limit the number of shares included in any such registration under specified circumstances. Upon such a request, we are required to effect the registration as expeditiously as possible. An aggregate of approximately 33.8 million shares of common stock are entitled to these demand registration rights.

Piggyback Registration Rights

If we propose to register any of our securities under the Securities Act of 1933, as amended, either for our own account or for the account of other stockholders, the holders of Registrable Shares and Oxford will each be entitled to notice of the registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of a managing underwriter to limit the number of shares included in any such registration under specified circumstances. An aggregate of approximately 34.1 million shares of common stock are entitled to these piggyback registration rights. The holders of piggyback registration rights under our registration rights agreement and Oxford have waived these rights as they may apply to the filing of the registration statement of which this prospectus is a part.

Registration on Form S-3

If we are eligible to file a registration statement on Form S-3, the holders of Registrable Shares will be entitled, upon their written request, to have such shares registered by us on a Form S-3 registration statement at our expense, provided that such requested registration has an anticipated aggregate offering size to the public of at least $1.0 million and subject to other specified conditions and limitations. An aggregate of approximately 33.8 million shares of common stock are entitled to these Form S-3 registration rights.

Expenses of Registration

We will pay all expenses relating to any demand, piggyback or Form S-3 registration, other than underwriting discounts and commissions, subject to specified conditions and limitations.

Termination of Registration Rights

The registration rights granted under the registration rights agreement will terminate on August 4, 2025 or, if earlier, with respect to a particular holder, at such time as that holder and its affiliates may sell all of their shares of common stock pursuant to Rule 144 under the Securities Act without any restrictions on volume.

Preferred Stock

Pursuant to our amended and restated certificate of incorporation, or the Restated Certificate, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or stock exchange listing rules), to designate and issue up to 5,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the common stock, and to increase or

decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.

The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.

Our board of directors will fix the designations, voting powers, preferences and rights of the each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include:

•: the title and stated value;
•: the number of shares we are offering;
•: the liquidation preference per share;
•: the purchase price per share;
•: the dividend rate per share, dividend period and payment dates and method of calculation for dividends;
•: whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
•: our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
•: the procedures for any auction and remarketing, if any;
•: the provisions for a sinking fund, if any;
•: the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;
•: any listing of the preferred stock on any securities exchange or market;
•: whether the preferred stock will be convertible into our common stock or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted;
•: whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted;
•: voting rights, if any, of the preferred stock;
•: preemption rights, if any;
•: restrictions on transfer, sale or other assignment, if any;
•: whether interests in the preferred stock will be represented by depositary shares;

•: a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock;
•: the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;
•: any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and
•: any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.

The General Corporation Law of the State of Delaware, or DGCL, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.

Antitakeover Effects of Provisions of Charter Documents and Delaware Law

Charter Documents. Our Restated Certificate and Amended and Restated Bylaws, or Bylaws, each as amended to date, include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control or management of our company. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation's certificate of incorporation provides otherwise. Our Restated Certificate does not provide otherwise. In addition, the Restated Certificate provides that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing. Further, our Bylaws limit who may call special meetings of the stockholders. Our Restated Certificate does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our Bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals. These and other provisions of our Restated Certificate and Bylaws and Delaware law could discourage potential acquisition proposals and could delay or prevent a change in control or management of our company.

Delaware Takeover Statute. We are subject to Section 203 of the DGCL, which regulates acquisitions of some Delaware corporations. Section 203 generally prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years following the date of the transaction in which the person became an interested stockholder, unless:

•: the board of directors of the corporation approved the business combination or the other transaction in which the person became an interested stockholder prior to the date of the business combination or other transaction;
•: upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers of the corporation and shares issued under employee stock plans under which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

•: on or subsequent to the date the person became an interested stockholder, the board of directors of the corporation approved the business combination and the stockholders of the corporation authorized the business combination at an annual or special meeting of stockholders by the affirmative vote of at least 66²/3% of the outstanding stock of the corporation not owned by the interested stockholder.

Section 203 of the DGCL defines a "business combination" to include any of the following:

•: any merger or consolidation involving the corporation and the interested stockholder;
•: any sale, transfer, pledge or other disposition of 10% or more of the corporation's assets or outstanding stock involving the interested stockholder;
•: subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any of its stock to the interested stockholder;
•: any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or
•: the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an "interested stockholder" as any person who, together with the person's affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock.

Section 203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent's address is 250 Royall Street, Canton, Massachusetts 02021. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series.

Listing on the NYSE American

Our common stock is listed on the NYSE American under the symbol "SENS."

DESCRIPTION OF DEBT SECURITIES

We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.

We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.

The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities.

General

The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.

We may issue the debt securities issued under the indenture as "discount securities," which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with "original issue discount," or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.

We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:

•: the title of the series of debt securities;
•: any limit upon the aggregate principal amount that may be issued;
•: the maturity date or dates;
•: the form of the debt securities of the series;
•: the applicability of any guarantees;
•: whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;

•: whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination;
•: if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined;
•: the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;
•: our right, if any, to defer payment of interest and the maximum length of any such deferral period;
•: if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;
•: the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder's option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;
•: the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;
•: any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;
•: whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities;
•: if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders' option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;
•: if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;
•: additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant;
•: additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;
•: additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;

•: additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
•: additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;
•: the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;
•: whether interest will be payable in cash or additional debt securities at our or the holders' option and the terms and conditions upon which the election may be made;
•: the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts of the debt securities of the series to any holder that is not a "United States person" for federal tax purposes;
•: any restrictions on transfer, sale or assignment of the debt securities of the series; and
•: any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.

Conversion or Exchange Rights

We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.

Consolidation, Merger or Sale

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.

Events of Default under the Indenture

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue:

•: if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose;
•: if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any;

•: if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and
•: if specified events of bankruptcy, insolvency or reorganization occur.

If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, of such series of debt securities due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.

The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.

Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:

•: the direction so given by the holder is not in conflict with any law or the applicable indenture; and
•: subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.

A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if:

•: the holder has given written notice to the trustee of a continuing event of default with respect to that series;
•: the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request;
•: such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and
•: the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.

These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.

We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.

Modification of Indenture; Waiver

Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may change an indenture without the consent of any holders with respect to specific matters:

•: to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
•: to comply with the provisions described above under "Description of Debt Securities—Consolidation, Merger or Sale";
•: to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
•: to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture;
•: to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;
•: to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;
•: to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under "Description of Debt Securities—General" to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;
•: to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
•: to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.

In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:

•: extending the fixed maturity of any debt securities of any series;
•: reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or

•: reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.

Discharge

The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:

•: provide for payment;
•: register the transfer or exchange of debt securities of the series;
•: replace stolen, lost or mutilated debt securities of the series;
•: pay principal of and premium and interest on any debt securities of the series;
•: maintain paying agencies;
•: hold monies for payment in trust;
•: recover excess money held by the trustee;
•: compensate and indemnify the trustee; and
•: appoint any successor trustee.

In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.

Form, Exchange and Transfer

We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.

At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.

Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.

We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a

change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.

If we elect to redeem the debt securities of any series, we will not be required to:

•: issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or
•: register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.

Information Concerning the Trustee

The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.

Payment and Paying Agents

Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.

We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.

All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.

Governing Law

The indenture and the debt securities, and any claim, controversy or dispute arising under or related to the indenture or the debt securities, will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.

Outstanding Debt Securities

On June 30, 2016, we entered into an Amended and Restated Loan and Security Agreement with Oxford and SVB, or the Lenders. Pursuant to the Amended and Restated Loan and Security

Agreement, we have borrowed an aggregate principal amount of $25.0 million in the following three tranches: $15.0 million, or the Tranche 1 Term Loan; $5.0 million, or the Tranche 2 Term Loan; and $5.0 million, or the Tranche 3 Term Loan. We refer to each of the tranches as a Term Loan, and collectively, the Term Loans. The funding conditions for the Tranche 1 Term Loan were satisfied as of June 30, 2016. Therefore, we issued secured notes to the Lenders for aggregate gross proceeds of $15.0 million, or the Notes, on June 30, 2016. We used approximately $11.0 million from the proceeds from the Notes to repay the outstanding balance under our previously existing Loan and Security Agreement with Oxford, dated as of July 31, 2014, including the applicable final payment fee due thereunder of $1 million. On November 22, 2016, the funding conditions for the Tranche 2 Term Loan were satisfied; therefore we issued secured notes to the Lenders for aggregate gross proceeds of $5.0 million. On March 29, 2017, the funding conditions for the Tranche 3 Term Loan were satisfied; therefore we issued secured notes to the Lenders for aggregate gross proceeds of $5.0 million. The maturity date for all Term Loans is June 1, 2020, or the Maturity Date.

The Term Loans bear interest at a floating annual rate of 6.31% plus the greater of (i) 90-day U.S. Dollar LIBOR reported in the Wall Street Journal or (ii) 0.64%, provided that the minimum floor interest rate is 6.95%, and require monthly payments. The monthly payments initially consist of interest-only. Beginning on January 1, 2018, the monthly payments converted to payments of principal and monthly accrued interest, with the principal amount being amortized over the ensuing 30 months.

We may elect to prepay all Term Loans prior to the Maturity Date subject to a prepayment fee equal to 3.00% if the prepayment occurs within one year of the funding date of any Term Loan, 2.00% if the prepayment occurs during the second year following the funding date of any Term Loan, and 1.00% if the prepayment occurs more than two years after the funding date of any Term Loan and prior to the Maturity Date.

The Amended and Restated Loan and Security Agreement contains customary events of default, including bankruptcy, the failure to make payments when due, the occurrence of a material impairment on the Lenders' security interest over the collateral, a material adverse change, the occurrence of a default under certain other agreements entered into by us, the rendering of certain types of judgments against us, the revocation of certain of our government approvals, violation of covenants, and incorrectness of representations and warranties in any material respect. Upon the occurrence of an event of default, subject to specified cure periods, all amounts owed by us would begin to bear interest at a rate that is 5.00% above the rate effective immediately before the event of default, and may be declared immediately due and payable by Lenders.

The Notes are collateralized by all of our consolidated assets. The Notes also contain certain restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions, as well as financial reporting requirements.

At maturity (or earlier prepayment), we are also required to make a final payment equal to 9.00% of the aggregate principal balances of the funded Term Loans. This fee is being accrued as additional interest expense over the term of the Notes using the effective interest method.

In January 2018, we issued $50.0 million in aggregate principal amount of convertible senior subordinated notes, or the 2023 Notes, and in February 2018, we issued an additional $3.0 million in aggregate principal amount of 2023 Notes. The 2023 Notes are general, unsecured, senior subordinated obligations and bear interest at a rate of 5.25% per year, payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2018. The 2023 Notes will mature on February 1, 2023, unless earlier repurchased or converted. Payment of the principal of, and accrued and unpaid interest, if any, on the maturity date, and the fundamental change repurchase price of (excluding cash payable in lieu of delivering fractional shares of our common stock), the 2023 Notes is subordinated to

the prior payment in full in cash or other payment satisfactory to the holders of senior debt, of all existing and future senior debt, which includes our indebtedness under the Amended and Restated Loan and Security Agreement with the Lenders and any refinancing thereof.

The 2023 Notes will be convertible into shares of our common stock at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. The conversion rate is initially 294.1176 shares of common stock per $1,000 principal amount of 2023 Notes (equivalent to an initial conversion price of approximately $3.40 per share of common stock), subject to customary adjustments. Holders who convert on or after the date that is six months after the last date of original issuance of the 2023 Notes but prior to February 1, 2021, may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of our common stock. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2023 Notes in connection with such a corporate event.

DESCRIPTION OF WARRANTS

The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.

We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants.

General

We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including:

•: the title of such securities;
•: the offering price or prices and aggregate number of warrants offered;
•: the currency or currencies for which the warrants may be purchased;
•: if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;
•: if applicable, the date on and after which the warrants and the related securities will be separately transferable;
•: if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
•: in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise;
•: in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one

warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise;

•: the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;
•: the terms of any rights to redeem or call the warrants;
•: the terms of any rights to force the exercise of the warrants;
•: any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;
•: the dates on which the right to exercise the warrants will commence and expire;
•: the manner in which the warrant agreements and warrants may be modified;
•: a discussion of any material or special U.S. federal income tax consequences of holding or exercising the warrants;
•: the terms of the securities issuable upon exercise of the warrants; and
•: any other specific terms, preferences, rights or limitations of or restrictions on the warrants.

Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:

•: in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or
•: in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.

Exercise of Warrants

Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.

Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant.

Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the

applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.

Governing Law

Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.

Enforceability of Rights by Holders of Warrants

Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.

Outstanding Warrants to Purchase Common Stock

As of December 31, 2017, we had outstanding warrants to purchase 116,581 shares of common stock at an exercise price of $3.86 per share, which warrants expire June 30, 2026, warrants to purchase 63,025 shares of common stock at an exercise price of $2.38 per share, which warrants expire November 22, 2026, warrants to purchase 80,645 shares of common stock at an exercise price of $1.86 per share, which warrants expire on March 29, 2027, and warrants to purchase 167,570 shares of common stock at an exercise price of $1.79 per share, which warrants expire on November 2, 2020, July 14, 2021, and August 19, 2021. The number of shares of common stock issuable upon the exercise of each warrant is subject to adjustment from time to time upon the occurrence of specified events.

LEGAL OWNERSHIP OF SECURITIES

We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the "holders" of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as "indirect holders" of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.

Book-Entry Holders

We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary's book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.

Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.

As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary's book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.

Street Name Holders

We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in "street name." Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.

For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.

Legal Holders

Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who

hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.

For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.

Special Considerations for Indirect Holders

If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out:

•: how it handles securities payments and notices;
•: whether it imposes fees or charges;
•: how it would handle a request for the holders' consent, if ever required;
•: whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;
•: how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and
•: if the securities are in book-entry form, how the depositary's rules and procedures will affect these matters.

Global Securities

A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.

Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form.

A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under "—Special Situations When a Global Security Will Be Terminated." As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.

If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.

Special Considerations for Global Securities

As an indirect holder, an investor's rights relating to a global security will be governed by the account rules of the investor's financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.

If securities are issued only as global securities, an investor should be aware of the following:

•: an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;
•: an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;
•: an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;
•: an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;
•: the depositary's policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor's interest in the global security;
•: we and any applicable trustee have no responsibility for any aspect of the depositary's actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way;
•: the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and
•: financial institutions that participate in the depositary's book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities.

There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.

Special Situations When a Global Security Will Be Terminated

In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.

A global security will terminate when the following special situations occur:

•: if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;
•: if we notify any applicable trustee that we wish to terminate that global security; or
•: if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.

The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.

PLAN OF DISTRIBUTION

We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:

•: at a fixed price or prices, which may be changed;
•: at market prices prevailing at the time of sale;
•: at prices related to such prevailing market prices; or
•: at negotiated prices.

We may also sell equity securities covered by this registration statement in an "at the market" offering as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or through the facilities of the NYSE American or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale.

Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent.

A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:

•: the name or names of any underwriters, dealers or agents, if any;
•: the purchase price of the securities and the proceeds we will receive from the sale;
•: any over-allotment options under which underwriters may purchase additional securities from us;
•: any agency fees or underwriting discounts and other items constituting agents' or underwriters' compensation;
•: any public offering price;
•: any discounts or concessions allowed or reallowed or paid to dealers; and
•: any securities exchange or market on which the securities may be listed.

Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.

If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.

We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will

pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.

We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.

We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.

All securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.

Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise.

Any underwriters who are qualified market makers on the NYSE American may engage in passive market making transactions in the securities on the NYSE American in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement.

LEGAL MATTERS

Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP, Reston, Virginia.

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 2 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP's report, given on their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus.

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC's Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including us. The address of the SEC website is www.sec.gov.

We maintain a website at www.senseonics.com. Information contained in or accessible through our website does not constitute a part of this prospectus.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to "incorporate by reference" information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-37717. The documents incorporated by reference into this prospectus contain important information that you should read about us.

The following documents are incorporated by reference into this document:

•: our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and filed with the SEC on March 13, 2018;
•: our Current Reports on Form 8-K filed with the SEC on January 25, 2018, January 26, 2018 (as amended by Amendment No. 1 filed on January 26, 2018) and January 30, 2018, to the extent the information in such reports is filed and not furnished; and
•: the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on Form 8-A, filed with the SEC on March 11, 2016, including any amendments or reports filed for the purpose of updating such description.

We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.

We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to Senseonics Holdings, Inc., Attn: Investor Relations, 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005, telephone: (301) 515-7260.

Any statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus, modifies or supersedes such statement.

Table of Contents

$80,000,000

Common Stock

PROSPECTUS SUPPLEMENT

BTIG

, 2018

GRAPHIC 2 g170263.jpg G170263.JPG begin 644 g170263.jpg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end GRAPHIC 3 g1034913.jpg G1034913.JPG begin 644 g1034913.jpg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

S5]@DD81!N^?(E!R>.EQ59U%XDR=UB82D70D%!HZKDBF_="HN$ZE[5,UIUJS5*XVW5JY$; M>-?4M.@%NFO8BM85:IV)6#(!82)',L2^(=,S/)UX.H1CK=IDW'F&L&V-G<<5 M805L,I,W>).HK 7/)4\5")<_)QR.FY">F%(M9S',VK MYY"9AW%%RSKE.@8GU]NDBJL5%Y,.BH*2;L$2'.E%P;/S4Y, M.A*";*(CGSQ8Q$D#G#WG FP/>/N9D6+3$.WO),[&OG9&AKA,5Y[3Z"P'N.59 M:0NUL2AX!-%L":AETV;I\]^]F109+N1(@=S;I8](BD;"F:V3\@2\9DK[Z-P;HJ=9P62KY3,T:KTXW&JLHMW79&P;&MR&7FO\ LJ(^2X[#19"B-8Q6 MJ++QCP\^#T;?.=M\;M&>QMC%8:]:KOR>2;6?5I)QM45)7C<1%CL=MWQE A(*V;O@,7LKY08=842-SN6%3H&,X1%XLBF M8Q"+O@9"\< 4QN5EU![C"/<*J+C^UG7\$=_^75T[![0YMTSUN$J>U9G@S#V1 M,MN:O:"B9.>]4SK^ M4\N>)U[+6<:JGKU>LZEC+EBK"ZV$QR/6MJDFN83X>N8@Y\)&1+[Q/5C'M^_8 M*PQ_%/C?_P!%06M1.K?^UN[P?XG)C_62]A.Z2B8] MJT[=;I9\5RL77:K68]>6GIR25D(M1-C%QS8#+O'1TTE3D12*)S%3,( /&D3U MYRE[W@GL:M:%[9BFL<9B*@4&7KF;39,P K$(DB.2@8&)*9B([]/EL*7,T'-U MUJ8;SU'(I!( 1--I8=P"H5Q$F3".8& B)*2GQB._VZK65/QBG[\W_B'37.P' M^Y]=]'[[=#_1W2=00J=-?J BH"(_\ 0Z9,V4;:=PE+ MZ(N\7"EMPKDJMY>MYMQ/R5QI,U60872Q!8:-46$$,1 K$*\>A+O&CIM'^$01 M=+-EDTNX2>KUJO8NKE:-@UH59;+7&*7G()7$Q+&E M$ $3$D41/2%\(:SL=#8=D;=P.9IK9H>TUULM8RX@&/;45ZD@34A!M9,=@ 9D MCG[#$S]NDUS_ (9OWQOYQTZ3[/=2H?)/3DW$8[L)#*5^^YRRK3)U,@)F.>'M M.'<;0QK]HDY*'AG<,W*8#W)&U7?45LN#N\;Q#UJH92E9LC*7&? MM%5=YL[+F(*2@>P_:9F/MU8_3AJ^=H\D)9E\!EJ=%F"S%=K;^-MUZQ>Y"A]1 MLO;:_8WJ4:HZ632=RD"SC"&\V_:)J M36]7#I%L=\S1EF/#3V I^Y.K0Y8AQ[Z[V%9RU66!55(RNV62:MW"L19H4YU4 M:I:U&[EJ5HY5@+ F,6$9(P"6>9]J&Y/;W..ZWFK!N2\?OVXKE%:QK1#QNP*')CF%VZ[2E#DQS#]^]"E+R(C] (_ M1KN%.Q7DR_OV\/C[&M\NLF[6%)K&4NCV6QNW"_*93D2:P,0\.=0HJ) I\WDG MB)^()0.3EB+II=!S*]TO-7S#O7JIL=XJKKYG/1^%9APBI?,E.FO8[CF5P9QC MM4E&II78(JS47(N36R>1;KP+B'@F3Q:1-[<*G0N =*L4LAGTW'R^SDWP95QR MN8R#%)0*:&,!K6K'UUZZ%B1FE$P;K-E8$PQ\&<=O_P!0>[5;M# 6*=>$5L8@ M@&S.*P^.6UKC??R9J4HR]EA[S(0!KNX(KUS.%@7L]AW#[LNE9TJ.GU.XIA*2 M5[DY[?Y7*09$JD[9PBGV45G^6,=,R C9(12(DCUUQ)-Y!!=0Q%G+7P4FJ"B* MACZ51WM&._E*08*R<-M]>1J3YFK(LVN-;"R=/(])RDH^:-7BF1%TVCETT*LW M;NCH+$;+*$7.DH5,2&<4W7;5\8;OL!W+;]DQD=*M69BW&(EHM)LG+TNR1(^/ M6+96C*IF0;2E>>E(J@@8GDWS$SR%?)J1D@[0.B;NRZ.N]S:S/2XEQ?.YLQPU M.NXC,GX:@Y2UQZ\4182)+V.HQZ;VW4^1(B*2D@S=Q\E$-5#G*RL_*2*/U.OE[SL@ 5;;6*6=BFRPRH-:)%WQTUV) M%D>ST[#R[A^7-"9AWZ+F=C=IU#!8?&S7QN6/,X(WL[7-QV/(C)6,Z M5N0D6\M7)2(44\!^D_0(V,)2.V;ETP<-72R577*NFU:[[T5)/; >ER8HT6.; MYFM..%(U:F6;*AYJ8<+.VKR%$\',3[*MJ0[*USD0JL@^DP39OEEIJ+DSZB"E M:Q/1#U2/G:U,1DBAR15C,UZ182"/!S$$BK218(NT@ Y#D[#IE#O(LUWGF7:>6->K:<.C+G)_+JNLV:"+F0MD]'>(BA2^++<>3 MSF19,OL'*I-$% F4]>"X[IEBR+?Z/0*BP=REIN]OK52KD3=AFF45& MHMD/@JKYITFH!3<$ I#G5$J13F"U;CVYVC%HU57.Y4;-F[=1PNS\:+,@1+&V\[M@VI&3E*Q2!D+I M:I9HT:-+QTQO7SV%]. $ >>"B)0Y_*!1 !_+S\=8*C)DW42(S^8B?\Q$]9I2% "\ ( !0 M "@(@4 /0 * ]O !Z ''P]/AKZ . #Z@#@/T!HT:CJ>T?V_Z_ZB.N=& MC1HZ.N!* _D]>?01+R/Y>!#G\_.L(6C05O%%JV%7Q /XHH)"KW@(<'\02=_> M' <&[NX. X'T#1HU,3,?B9C_ !U$Q$_F(GM^.\=^W68!0#@>.1#D0$1$PAS\ M>!,(B'/Y-?6C1J.IZXX#Z@_1HX#Z@_1HT:.CKG0( /Q !^W1HT='7' ?4'Z MUSHT:.CK@2@/U@(\! M$1,(<_'@1$1 /R /&OK1HU'4]&OGM+^4/HX 1 /7_! 0#_-HT:.CK#1:-$E M.DU;I'X,'>D@DDIP(>H =,I3 _3P/KK- H!\ ]>..1Y$W'// F'D1#GZQT: M-3,S/YF9_P _?J(B(_$1'^([?_G7.C1HU'4]<"4!^/QXXY 1 >/JY 0'C\^L M91N@=9-4Z")U2=O8J=,AU2<"(AV*&*)R<"(B':8.!$1#U$=&C1WG^_43$3^8 MB?\ /WZR.TOU<^O(0$=&C1T=?S0012)V(I)HD PF[$2@ MD3N$ Y$2I@4HB/TB(>H[1'>8B(F?S/;\_P"? +[]?6C1HU'4]?_]D! end